Market Overview
| Period | Price Change |
|---|---|
| 1 Day | -1.32% |
| 1 Week | +0.19% |
| 1 Month | +13.02% |
| YTD | +9.12% |
EMR is showing strong momentum over the past month with a 13% gain, though it pulled back slightly in the most recent session.
| Score Type | Rating (0-100) |
|---|---|
| Total Score | 69.4 |
| Growth | 74.0 |
| Momentum | 55.1 |
| Quality | 56.9 |
| Value | 41.8 |
Emerson scores particularly well on Growth (74.0) and has a solid Total Score of 69.4. The stock shows strength in its growth profile and quality metrics, though the value score suggests it may not be deeply undervalued at current levels.
| Metric | Value | Change |
|---|---|---|
| Short Interest % of FF | 2.28% | Down 12.9% (1 month) |
| Shares Short | 12.64M | Down 11.7% (1 week) |
| Days to Cover (DTC) | 3.96 | - |
| Cost to Borrow | 0.42% | Down 5.2% (1 month) |
| Availability % of SI | 1,570.8% | Very high |
| Utilization | 6.06% | Low |
Short interest remains very low at just 2.28% of free float and has been declining steadily. The extremely high availability (over 1,500% of current short interest) and low utilization (6.06%) indicate minimal shorting pressure. Cost to borrow is negligible at 0.42%.
| Metric | Value |
|---|---|
| Put/Call Ratio (PCR) | 0.635 |
| 20-Day Mean PCR | 0.704 |
| Z-Score | -2.07 |
The PCR of 0.635 is below the 20-day average, with a z-score of -2.07 indicating unusually bullish options sentiment. More calls are being traded relative to puts compared to recent weeks.
| Metric | Value |
|---|---|
| Revenue (TTM) | $18.93B |
| EBITDA | $5.41B |
| Net Income | $2.77B |
| EPS | $6.49 |
| EV/EBITDA | 16.2x |
| Dividend Yield | 1.55% |
Emerson generates nearly $19B in annual revenue with healthy profitability. The company produces strong operating cash flow of $4.0B and maintains modest capex of $454M.
Next Earnings: May 5, 2026 at 8:00 PM UTC (Q2 2026 Results)
EMR is a large-cap industrial with strong growth characteristics and solid quality metrics. The stock has rallied 13% over the past month and shows bullish options positioning. Short interest is minimal and declining. With analysts forecasting 13% upside and earnings due in early May, the stock appears positioned for continued strength, though the recent momentum suggests some caution as it approaches overbought territory technically.
Technical: RSI at 59 (neutral-to-bullish)
Short Squeeze Risk: Very low (minimal short interest)
Options Sentiment: Bullish (low PCR)
This is not financial advice. All data is provided for informational purposes only and may contain errors.
See the live data behind this article on ORTEX.
Open EMR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
